TACTICAL THERAPEUTICS’ first drug candidate, carboxyamidoimidazole CTO has unique properties of improved bioavailability and delivery to target cells, improved efficacy in inhibiting tumors and higher clearance rate and reduced toxicity (compared with a related drug, CTO, abandoned by the NCI). CTO is being developed on the Fast Track.
Pharmacokinetics
TACTICAL THERAPEUTICS’ first drug candidate, carboxyamidoimidazole CTO has unique properties of improved bioavailability and delivery to target cells, improved efficacy in inhibiting tumors and higher clearance rate and reduced toxicity (compared with a related drug, CAI, abandoned by the NCI). CTO is being developed on the Fast Track.
Efficacy
CAI Orotate is an important candidate for cancer therapy because CAI has been shown to:
CAI Orotate was more effective in inhibiting a variety of experimental tumors including prostate, melanoma, colon, etc. CAI Orotate, given alone, is equally effective in inhibiting colon tumors in mice in comparison with AVASTIN alone.
When given in Combination with 5 Fluorouracil, CTO maybe more effective in inhibiting the colon tumors compared with AVASTIN + 5-FU.
Toxicology
Tactical’s Product, CTO, has improved oral bioavailability, is more effective and less toxic in animal cancer models than CAI. CAI, was tested for twenty years, by scientists at the National Cancer Institute (NCI) and was found to cause serious side effects in cancer patients entered in several Phase II clinical trials. CAI has been abandoned because of this. NCI has given a Cross Reference letter to its IND for CAI to TACTICAL THERAPEUTICS.
Toxicology
Tactical’s CTO is an important candidate for cancer therapy because CAI has been shown to
Inhibit angiogenesis, inhibit intracellular calcium influx, inhibit signal transduction and ultimately down-regulation of the production of regulatory proteins responsible for tumor invasion and metastases,
Inhibit VEGF,
Tactical’s CTO has comparable anti-tumoractivity to AVASTIN, yet is significantly less expensive.
Cancer Cell Processes
Tactical’s CTO is an important candidate for cancer therapy because CAI has been shown to:
Inhibit the proliferation and invasion of several tumor cell lines in vitro, and in animal tumor models,
Reduce prostate-specific antigen production,
Inhibition of cyclooxygenase, and
Induce apoptosis.
Tactical’s CTO is more effective as an anticancer drug in animal cancer models than Merck’s CAI
Tactical’s Product, CTO, has improved oral bioavailability, is more effective and less toxic in animal cancer models than CAI. CAI, was tested for twenty years, by scientists at the National Cancer Institute (NCI) and was found to cause serious side effects in cancer patients entered in several Phase II clinical trials. CAI has been abandoned because of this. NCI has given a Cross Reference letter to its IND for CAI to TACTICAL THERAPEUTICS.